---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-019889"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:14:45.594922+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership

## Summary
- Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.
- Cash burn reduced to $3.9M in Q1; management targets average quarterly burn below $5M.
- Announced global commercialization partnership with Bio-Rad; Bio-Rad also bought 8.99% stake via $15.8M equity private placement.
- On track to ship RUO GraftAssure kits to initial customers in Asia, US, and EU during Q2 2024; IVD kit under development for FDA.

## SEC filing metadata
- accession: 0001493152-24-019889
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/0001493152-24-019889-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-019889
- JSON: https://secwatch.observer/filing/0001493152-24-019889.json
- Plain text: https://secwatch.observer/filing/0001493152-24-019889.txt

## Key facts
- Earnings Releases
  Insight Molecular Diagnostics Inc. reported the quarter ended March 31, 2024 results: revenue $176,000.
  - Period: the quarter ended March 31, 2024
  - Revenue: $176,000
  - Result: reported results
  source text: Net revenue for the three months ended March 31, 2024 was $176,000, a decrease of 41% compared to the same period in 2023, due to decreased revenue from our Pharma Services business.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1642380/000149315224019889/0001493152-24-019889-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.